COMPANY
Immunoshield Therapeutics
Funding and NIH signals
- NIH award NIH awarded $935K (SBIR Phase II 5R44DK136496-03, continuation, notice Jul 30, 2026). NIH RePORTER 5R44DK136496-03 (Jul 30, 2026)
Evidence (1 event)
- Jul 30, 2026 · NIH RePORTER 5R44DK136496-03
Organization: IMMUNOSHIELD THERAPEUTICS INC.; City/State: CHANDLER, AZ; Project number: 5R44DK136496-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-30; FY total cost (award amount): 935197; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Hydrogel injection molded islet macroencapsulation devices to treat diabetes in a non-human primate model; Organization type: Domestic For-Profits
- Jul 30, 2026 · NIH RePORTER 5R44DK136496-03